播放中国国产国语纯一级黄片免费看, 大鸡吧快来啊阿啊阿啊黄片在线播放, 中文精品日韩网站在线观看视频免费, 别揉我奶头~嗯~啊~一区二区三区,AV无码播放一级毛片免费古装,亚洲春色一区二区三区,91大神极品,美国一级大黄一片免费下载,午夜爽爽爽男女免费观看软件

Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Fesoterodine fumarate, developed by Pfizer, is a prodrug used for the treatment of overactive bladder syndrome. It is rapidly hydrolyzed in the blood after oral administration to its active metabolite, 5-hydroxymethyl tolterodine (5-HMT), which is also the active metabolite of tolterodine. Fesoterodine fumarate is an antimuscarinic agent and a muscarinic receptor antagonist, chemically characterized as a white solid.

286930-03-8

Post Buying Request

286930-03-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

286930-03-8 Usage

Uses

Used in Pharmaceutical Industry:
Fesoterodine fumarate is used as a muscarinic receptor antagonist for the treatment of Lower Urinary Tract Symptoms (LUTS). It helps alleviate the symptoms of overactive bladder by blocking the action of acetylcholine, a neurotransmitter that can cause involuntary muscle contractions in the bladder.
Additionally, Fesoterodine fumarate is used as an alternative to Tolterodine (T535800) due to its similar therapeutic effects and mechanism of action. This makes it a valuable option for patients seeking relief from LUTS and overactive bladder syndrome.

Biological activity

Fesoterodine Fumarate (SPM 907) is a prodrug of the muscarinic receptor antagonist 5-hydroxymethyl tolterodine, used to treat overactive bladder.

Side effects

The most common side effects was dry mouth, which was observed in the placebo group, the product 4 in the Phase II and Phase III clinical trials (a total of 2 859 patients, 2 288 taking this product for 8 to 12 weeks). The incidences of dry mouth at mg/d and 8 mg/d were 7%, 19%, and 35%, respectively, and the incidences of drug discontinuation due to dry mouth were 0.4%, 0.4%, and 0.8%, respectively. The second most common adverse reaction was constipation. The incidence of constipation in the placebo group and the 4 mg/d and 8 mg/d groups of this product was 2%, 4% and 6%, respectively. Other reported adverse events included loss of appetite, nausea, epigastric pain, urinary tract infection, upper respiratory tract infection, dry eyes, dysuria, urinary retention, cough, peripheral edema, back pain, insomnia, abnormal liver function, and rash.

Clinical Use

Antimuscarinic:Symptomatic treatment of urinary incontinence, frequency or urgency

Drug interactions

Potentially hazardous interactions with other drugs Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide. Antifungals: dose reduction advised with itraconazole and ketoconazole. Antivirals: dose reduction advised with atazanavir, indinavir, ritonavir and saquinavir. Induction of CYP3A4 may lead to subtherapeutic plasma levels. Concomitant use with CYP3A4 inducers (e.g. carbamazepine, rifampicin, phenobarbital, phenytoin, St John's Wort) is not recommended. Co-administration of a potent CYP2D6 inhibitor may result in increased exposure and adverse events. A dose reduction to 4 mg may be needed' See 'Other information'

Metabolism

Molecular weight (daltons) 527.7 % Protein binding 50 (metabolite) % Excreted unchanged in urine 70 (as metabolites) Volume of distribution (L/kg) 169 Litres Half-life - normal/ESRF (hrs) 7 / -

Check Digit Verification of cas no

The CAS Registry Mumber 286930-03-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,6,9,3 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 286930-03:
(8*2)+(7*8)+(6*6)+(5*9)+(4*3)+(3*0)+(2*0)+(1*3)=168
168 % 10 = 8
So 286930-03-8 is a valid CAS Registry Number.
InChI:InChI=1/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1

286930-03-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (E)-but-2-enedioic acid,[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate

1.2 Other means of identification

Product number -
Other names Toviaz

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:286930-03-8 SDS

286930-03-8Downstream Products

286930-03-8Relevant articles and documents

ANTIMUSCARINIC COMPOUND HAVING A LOW CONTENT OF IMPURITIES

-

Paragraph 0061, (2016/02/20)

Substantially stable to degradation Fesoterodine fumarate, a process for its preparation and a process for the synthesis of specific degradation impurities of Fesoterodine fumarate are disclosed.

PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES

-

Paragraph 0240-0242, (2015/04/15)

3,3-diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, can be produced by treating a compound of formula (II) with a chiral alcohol to yield the diastereomeric esters of formula (IV) and (IV′), which can be further transformed into a compound of formula (I), or an enantiomer, solvate or salt thereof, wherein R1 is C1-C8 alkyl; and R2 and R3, independently of one another, represent H or C1-C6 alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound.

PROCESS FOR THE PREPARATION OF 2-(3-N,N-DIISOPROPYLAMINO-1-PHENYLPROPYL)-4-HYDROXYMETHYL-PHENOL AND ITS DERIVATIVES

-

, (2014/02/15)

The invention concerns a process for the preparation of 2-(3-N,N- diisopropylamino-l-phenylpropyl)-4-hydroxymethyl-phenol and its derivatives, particularly the corresponding (R) 4-trityloxymethyl derivative, useful as intermediate form in the synthesis of Fesoterodine and its salts, in particular for the preparation of Fesoterodine fumarate salt.

PROCESS FOR THE PREPARATION OF FESOTERODINE OR ITS SALTS

-

, (2013/04/13)

The present invention relates to a process for the preparation of fesoterodine or its salts.

PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES

-

, (2013/08/15)

The invention relates to a process for obtaining 3,3-diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, comprising treating a compound of formula (II) with a chiral alcohol to yield the diastereomeric esters of formula (IV) and (IV'), which can be further transformed into a compound of formula (I), or an enantiomer, solvate or salt thereof, wherein R1 is C1-C8 alkyl; and R2 and R3, independently of one another, represent H or C1-C6 alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound.

A PROCESS FOR PREPARING FESOTERODINE

-

, (2012/10/18)

The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of fesoterodine and pharmaceutically acceptable salts thereof which involves use and preparation of R(+) benzyl tolterodine and fumarate salt of R(+)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol.

PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST

-

, (2012/08/07)

The present invention relates to novel and improved processes for the preparation of (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenylisobutyrate represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.

PROCESSES FOR THE PREPARATION OF FESOTERODINE

-

, (2012/03/26)

The invention relates to improved process for the preparation of fesoterodine and its pharmaceutically acceptable salt, specifically fesoterodine fumarate of formula (1). The invention relates to solid state forms of a novel salt of fesoterodine and process for the preparation thereof. The invention also relates to highly pure fesoterodine fumarate substantially free of impurity X at RRT 1.37. The invention also provides solid particles of pure fesoterodine fumarate wherein 90 volume-percent of the particles (D90) have a size of higher than 200 microns.

PROCESS FOR PREPARATION OF PHENOLIC MONOESTERS OF HYDROXYMETHYL PHENOLS

-

, (2011/11/30)

A process for the preparation of phenolic monoesters of 2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol by converting (±)6-halo-4-phenylchroman-2-one to (±)4-halo-2-(3-hydroxy-1-phenylpropyl)phenol. The two hydroxyl groups are protected and the protected compound is reacted with diisopropylamine to give (±)[3-(2-benzyloxy-5-halophenyl)-3-phenylpropyl]diisopropylamine. The halo substituent on the benzene ring is converted to corresponding benzyl alcohol and then the protection is removed to give racemic 5-HMT. Racemic 5-HMT is converted R enantiomer and then it is esterified.

The lactol route to fesoterodine: An amine-promoted Friedel-Crafts alkylation on commercial scale

Dirat, Olivier,Bibb, Andrew J.,Burns, Colin M.,Checksfield, Graham D.,Dillon, Barry R.,Field, Stuart E.,Fussell, Steven J.,Green, Stuart P.,Mason, Clive,Mathew, Jinu,Mathew, Suju,Moses, Ian B.,Nikiforov, Petar I.,Pettman, Alan J.,Susanne, Flavien

, p. 1010 - 1017 (2011/12/16)

We report the discovery and optimization of an amine-promoted Friedel-Crafts alkylation of cinnamaldehyde with 4-hydroxymethyl phenol. This reaction has been used successfully on commercial scale (200 kg) in the context of the manufacture of fesoterodine, a muscarinic antagonist used for the treatment of overactive bladder. Reductive aminations of diisopropylamine and lactol 4 are also discussed, as well as the resolution of the racemic amine rac-2 into its enantiomerically pure form.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 286930-03-8